Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Olstein Capital Management L.P.

Olstein Capital Management L.P. lessened its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 85,000 shares of the medical equipment provider's stock after selling 7,000 shares during the period. Olstein Capital Management L.P.'s holdings in Hologic were worth $6,924,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its stake in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the period. Swedbank AB purchased a new stake in shares of Hologic in the 1st quarter worth approximately $120,827,000. Black Creek Investment Management Inc. boosted its stake in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Mackenzie Financial Corp increased its holdings in Hologic by 1,023.3% during the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider's stock valued at $66,506,000 after buying an additional 815,960 shares during the period. Finally, Marshall Wace LLP bought a new position in Hologic in the second quarter worth approximately $39,427,000. Institutional investors own 94.73% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a report on Tuesday. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Stephens reissued an "overweight" rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Mizuho cut their price objective on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday. Finally, Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $89.25.

Hologic Stock Performance

Hologic stock traded down $1.20 during trading hours on Thursday, hitting $79.29. 1,456,026 shares of the stock traded hands, compared to its average volume of 1,594,685. The firm's 50 day moving average price is $81.05 and its 200-day moving average price is $78.12. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The stock has a market capitalization of $18.42 billion, a price-to-earnings ratio of 24.17, a P/E/G ratio of 3.03 and a beta of 0.98. Hologic, Inc. has a 1 year low of $66.93 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a return on equity of 20.11% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the firm earned $0.89 earnings per share. Hologic's revenue for the quarter was up 4.5% on a year-over-year basis. As a group, equities analysts expect that Hologic, Inc. will post 4.36 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.